

**ANTICANCER ACTIVITIES AND METABOLITE FINGERPRINTING OF UPLC-QToF-MS/MS METHOD FROM *Chrysanthemum cinerariifolium* (Trev)****Anik Listiyana<sup>1</sup>, Nia Ayu Lestari<sup>1</sup>, Santia Irawati<sup>1</sup>, Yen Yen Ari Indrawijaya<sup>1</sup>, Rahmi Annisa<sup>1</sup>, Weka Sidha Bhagawan<sup>1</sup>, Roihatul Mutiah\*<sup>1</sup>, Burhan Ma'arif**<sup>1</sup>*Department of Pharmacy, Faculty of Medical and Health Science, Universitas Islam Negeri Mulana Malik Ibrahim, Malang, Indonesia*

\*Corresponding author: roiha@farmasi.uin-malang.ac.id

**ABSTRACT**

*Chrysanthemum cinerariifolium* (*C. cinerariifolium*) is an empirically proven medicinal plant that has anticancer activities. This study aimed to profile metabolites, and cytotoxic activity of root, leaf, stem, and root extracts *C. cinerariifolium* on T47D cells and to determine the correlation of metabolite content with cytotoxic activity. The metabolite profile was carried out using UPLC-QToF-MS / MS, and cytotoxic activity was carried out using the MTT method. The results obtained in the form of a chromatogram were processed with the application *Masslynk* so that a metabolite profile data obtained. The data is then analyzed statistically using *Principal Component Analysis* (PCA). The results obtained on metabolite profiling showed that there were differences in metabolite profiles in the roots, stems, leaves, and chrysanthemums. The characteristic compounds in the flower section are *D - (-) - Morphine* and in the leaf part of *genistein* and *N - [(5-Chloro-1,2,3-thiadiazol-4-yl) methyl] - 1- (2-isopropyl-4 -methyl-1,3-thiazol-5-yl) -N-methyl ethanolamine*. The major compounds in the roots, stems, and leaves are *Orphenadrine* with successive percentages of 9.11%, 10.16%, and 3.24%, and the major compounds in the flower section are *D - (-) - Morphine* with a percentage of 10, 86%. Furthermore, the results of the cytotoxic activity test showed differences in anticancer cytotoxic activity in the parts of the flower, leaf, stem, and root of *C. cinerariifolium*. Besides, there is a relationship between the metabolite content and anticancer cytotoxic activity of each part of *C. cinerariifolium*. The higher the level of orphenadrine compounds in the plant, the higher the potential for anticancer.

Keywords: *C. cinerariifolium*, UPLC-QToF-MS/MS, T47D cells.**INTRODUCTION**

Chemoprevention is the use of natural materials to prevent (stop the activation of carcinogens, blocking) at the stage of initiation of carcinogenesis pressing (suppressing) cancer growth and restoring (reversing) the normal function of cellular regulation so as to reduce the development of cancer or reduce the possibility of progressive to invasive cancer [1][2]. Some chemoprevention agents from natural materials show high potential to be developed when clinically tested so that it becomes a priority for further research, including flavonoid and polyphenol compounds such as quercetin, luteolin, biochanin A, genistein [3].

One of the traditional medicinal plants which are rich in the content of quercetin flavonoids is chrysanthemum (*Chrysanthemum cinerariifolium*).

Chrysanthemum flower (*Chrysanthemum cinerariifolium*) is a plant of the family Asteraceae which has been used by the community as an ornamental plant because of its beautiful flowers. Empirical evidence (traditional use) shows that chrysanthemum plants have widely used as antibacterial, anti-inflammatory, hypo-allergenic, and anticancer drugs [4][3]. Previous studies reported that chrysanthemums have potent anticancer activity [5]. It is also said that the most dominant compounds in chrysanthemum plants are terpenoid compounds and flavonoid compounds [6]. These compounds can act as anticancer. In breast cancer, flavonoid compounds and terpenoid groups play a role in inhibiting the mutation of the p53 gene so that it prevents excessive cell proliferation and can increase cell apoptosis [7][8]. The results of the antitumor activity test extracts of red chrysanthemums (*Chrysanthemum kunlun*) *in vitro* stated that flower extract *C. kunlun* could inhibit cell growth of Eca-109, H22 cells and HeLa cells [9].

Ophthalmology of secondary metabolites in a plant or natural product is a method that has widely developed today. One of the advantages of this method is that the stages of finding active compounds are shorter and require fewer samples than the method *Bioassay-Guided Isolation*. Also, metabolite profiling can be done to maintain the quality and consistency of the raw materials of herbal products used as traditional standardized medicines. Secondary metabolites are used not only from one organ part of the plant such as leaves, but rarely used parts do not rule out the possibility of containing secondary metabolites that have the potential to be developed, such as roots, stems, and flowers. It can be quickly done using an UPLC-QToF-MS/MS instrument. Based on this description, in this study profiling of metabolites and their correlation with the cytotoxic activity of extracts of flowers, leaves, stems, and roots of *Chrysanthemum cinerariifolium* (Trev.) On T47D breast cancer cells.

## MATERIALS AND METHODS

### Cell line and Reagents

The cell line used was T47D cells obtained from the Parasitology Laboratory of the Faculty of Medicine, Gadjah Mada University, Yogyakarta. The materials used for the test are the radix, caulis, folium, and flos *C. cinerariifolium*, technical ethanol 96%, and distilled water, n-hexane, ethyl acetate, H<sub>2</sub>SO<sub>4</sub> 10%, Complete RPMI 1640 medium (Gibco, USA), MK

MI99 (Gibco, USA), PBS, Trypsin-EDTA, DMSO (EMSURE ACS, Japan), SDS (Merck, Germany), ethanol extract 96% flower, ethanol extract 96% leaf, ethanol extract 96% stem , ethanol extract 96% of plant roots *C. cinerariifolium*, doxorubicin HCL 50 mg, and MTT solution (Bio Basic Canada Inc, Canada).

### **Plant Determination**

Determination of Plants was *C. cinerariifolium* (Trev) carried out at UPT Materia Medika Batu, East Java, Indonesia by number: 074/374/10272017 Plant specimens stored in the Pharmacognosy Laboratory of the Pharmacy Department of the Medical Faculty of Maulana Malik Ibrahim Malang.

### **Ethical Clearance**

This research has received ethical approval from the Health Research Ethics Commission (KEPK) of the Faculty of Medicine and Health Sciences, Maulana Malik Ibrahim the Islamic State University of Malang on April 23, 2018, with numbers 004 / EC / KEPK-FKIK / 2018.

### **Sample Preparation**

Sample *C.cinerariifolium* harvested by cut each piece of flowers, leaves, stems, and roots. Then each part is sorted early, washed, dried under the sun, and finally sorted. The dry sample is fertilized with a grinding machine and then weighed the powder.

### **Extraction of *C. cinerariifolium* The**

Powder of flowers, leaves, stems, and roots of *C. cinerariifolium* put into Erlenmeyer and ethanol 96% added with a ratio of 1:20. Mixture extracted using UAE (Ultrasonication Assisted Extraction) for 2 minutes with three replications. The filtrate for each part of *C. cinerariifolium* from UAE was evaporated using a rotary evaporator at a temperature of 50°C to produce the crude extract. A crude extract of flowers, leaves, stems, and roots concentrated using an oven at a temperature of 40°C until the texture of the extract becomes concentrated. Percentage of rendement calculated by the formula:

$$\% \text{ rendement} = \frac{\text{ExtractWeight of extract}}{\text{Simplicia weight}} \times 100\%$$

### **Thin Layer Chromatography (TLC)**

In the identification of compounds with TLC silica gel plate, 60 F<sub>254</sub> used as a stationary phase by optimizing mobile phase n-Hexane and ethyl acetate (5: 5); (7: 3); and (8: 2). While the appearance of the stain used is H<sub>2</sub>SO<sub>4</sub> 10%. Identify compound stains using the Thin Layer Chromatography (TLC) Visualizer.

### **Sample preparation for Analysis of Metabolite Profiling**

Determination of the metabolite types of ethanol extract of roots, stems, leaves, and chrysanthemums using the UPLC-QToF-MS/MS instrument with three replications. Carefully weighed 10.00 mg of ethanol extract of roots, stems, leaves, and chrysanthemum flowers, then dissolved in methanol into a 10 ml volumetric flask and added microsyringe was 5  $\mu$ l. The applied liquid was a mixture of (A) Water (HPLC grade) / formic acid (Merck, Darmstadt, Germany) 99.9 / 0.1 [v / v]; (B) Acetonitrile (Merck, Darmstadt, Germany) / formic acid 99.9 / 0.1 [v / v] and the system of gradient elution. The comparison presented in Table 1. Data obtained in the form of a chromatogram processed using software Masslynk version 4.1, so the data is in the way of peak area and m / z spectra of each detected peak and database [www.chemspider.com](http://www.chemspider.com). The data profile is then analyzed statistically by Principal Component Analysis (PCA) using software Minitab version 17.0.

### **Statistical Analysis**

The identification data from the extract component was classified based on the sample origin, and the percentages of the area were analyzed using the Principal Component Analysis (PCA) to get the loading plot and score plot. PCA was performed using Minitab 17 (Minitab Inc, Pennsylvania, USA)

### **Preparation of Samples for Cytotoxic Activity Test**

Flower, leaf, stem, and root extracts weighed as much as 10 mg, dissolved with DMSO and made seven kinds of concentration series namely 1000; 800; 600; 400; 200; 100; 50  $\mu$ g / mL. The positive control of doxorubicin is made with 7 types of concentration, namely 2000; 1000; 500; 250; 125; 62.5; 31.25 nM

### **Cytotoxicity Test**

Cytotoxicity tests were carried out on T47D cell cultures with RPMI medium. T47D cell culture was grown on 96 *well plates* and then incubated for 24 hours. After 24 hours the media was removed and washed with PBS, then each series of extract concentrations was inserted into each well with three replications and incubated for 24 hours. After 24 hours the media was removed and washed with PBS, then added MTT reagent 100  $\mu$ L to each well, including media control (without cells), then incubated again for 4 hours in a CO<sub>2</sub> incubator. After 4 hours the cell conditions under the inverted microscope were observed. Then a stopper of 100  $\mu$ L SDS 10% was added and incubated at room temperature for one night. Then read the absorbance value using ELISA reader and calculated cell viability using the following formula:

$$\text{Cell viability} = \frac{(\text{treatment abs} - \text{media control})}{\text{abs}(\text{cell control abs} - \text{media control abs})} \times 100\%$$

Results of cell viability obtained are carried out IC<sub>50</sub> analysis using Microsoft Excel. Then the data were analyzed by one way ANOVA to determine the cytotoxicity differences of each sample.

### **Correlation Analysis of Metabolic Content and Cytotoxic Activity**

Analysis of the correlation of metabolite content and cytotoxic activity was carried out using the Pearson correlation test. Pearson correlation test was used to test two variables, namely the percentage levels of orphenadrine compounds from parts of flowers, leaves, stems, roots with cytotoxicity activity in T47D cells. Correlation test results indicate whether there is a correlation between metabolite content and cytotoxic activity in that part.

## **RESULTS**

### **Thin Layer Chromatography (TLC)**

Thin Layer Chromatography (TLC) is a physicochemical separation method based on two phases, namely the mobile phase in the form of liquid and the stationary phase in the way of solids [10].

The optimization results obtained showed the best mobile phase in n-hexane and ethyl acetate (8: 2) by comparing before and after derivatization with H<sub>2</sub>SO<sub>4</sub> 10%. The results of the identification of TLC visualizers with UV 366 light showed differences in the separation of compounds between before and after spraying. The TLC plate after spraying shows many stains with several colors. It can be seen in the results of the R<sub>f</sub> obtained, the compound R<sub>f</sub> on the TLC plate after spraying was more than the value of R<sub>f</sub> on the TLC plate before spraying. The amount of TLC R<sub>f</sub> plate after spraying on flower, leaf, stem, and successive extracts is 9; 8; 10; and 11. According to Harborne [11], the yellow color with wavelengths 341-389 after being sprayed showed flavonol compounds and red-purple indicating terpenoid compounds. Whereas according to Muti'ah et al., [10] purple stains are suspected as sesquiterpenes. Flavonoid compounds and terpenoid groups play a role in health, one of which is to have anticancer activities [7][12].

Based on Figure 1 shows that there are differences in the chromatogram profile on the flowers, leaves, stems, and roots of *C. cinerariifolium*. The difference in the chromatogram indicates that there are differences in the metabolite content in each part of the organ *C. cinerariifolium*.

### Analysis of Metabolite Profiling with UPLC-QToF-MS/MS

The results obtained from the UPLC-QToF-MS/MS instrument were in the form of a chromatogram. The compounds that appear early on the *peak* chromatogram are polar compounds, and their polarity decreases at the *peak* next. At this stage, repetition carried out until a constant peak chromatogram obtained. The chromatogram obtained was processed using the application *Masslynx* version 4.1, so that the m/z spectra of each can be displayed *peak* on the chromatogram. Each peak of the chromatogram indicates the presence of one compound. Figure 2 is the result of a chromatogram of plant extract *C. cinerariifolium*. Based on the results of the chromatogram interpretation obtained from each peak, the prediction data found on chrysanthemum plants presented in table 2. It shows that there are differences in the compound content of the roots, stems, leaves, and flowers of *C. cinerariifolium*. Of the four parts of the organ, there is one dominant compound where the percentage greater than the other compounds, the compound is Orphenadrine (Figure 3). Orphenadrine is a flavonoid group compound that has activity tumor-preventing liver [13]. Figure 4, 5 and 6 are spectra of m/z compounds and the structure of the characteristic compounds found in parts of the chrysanthemum plant.

### Statistical Analysis Principal Component Analysis

Principal Component Analysis (PCA) is a mathematical method for reducing data, to reduce the dimensionality of a series of data and reveal a cluster [14]. The data used in the PCA analysis are data on the name of the compound found and the percentage of the area of the chrysanthemum plant (roots, stems, leaves, flowers). The results of the PCA analysis obtained are loading plots and plot scores (Figure 7). Loading plots show compounds that are thought to be characteristic compounds in parts of chrysanthemum plants. In this study marker compounds were specific compounds not found in other parts of the plant. The compound is D - (-) - Morphine (Figure 4) found in the flower section and in the leaf part N - [(5-Chloro-1,2,3-thiadiazol-4-yl) methyl] -1- (2-isopropyl-4-methyl-1,3 -thiazol-5-yl) -N-methylethanamine and genistein (Figures 5 & 6).

Based on Figure 5 shows that Loading plots can interpret the characteristic compounds in the flower section are D - (-) - Morphine and in the leaf part is N - [(5-Chloro-1,2,3-thiadiazol-4-yl) methyl] -1- (2-isopropyl-4- methyl-1,3-thiazol-5-yl) -N-methylhexanamine and genistein, whereas in the roots and stems there are no organ compounds found. The plot score shows that the contents of the root and stem compounds of *C. Cinerariifolium* have close physical and chemical properties.

### **Cytotoxic test for t47D cells Cytotoxicity**

The analysis aims to determine the anticancer cytotoxic differences of the parts of the flowers, leaves, stems, and roots of *C. cinerariifolium* by decreasing the percentage of living cells based on 50% Concentration ( $IC_{50}$ ) [15]. Cytotoxicity tests were carried out on T47D cells. The results of the cytotoxicity test presented in Figure 8 and Table 4.

Based on the results of  $IC_{50}$  values in Table 3, extracts that have cytotoxic activity against T47D cells are extracts of leaves, stems, and roots. An extract otherwise has a high cytotoxic activity when the value of  $IC_{50} < 500$  mg / mL and is said to have a weak activity where the  $IC_{50}$  values  $> 500$  pg / mL [16]. The  $IC_{50}$  amount of positive control is 208.82 nM. The results obtained were close to the value of  $IC_{50}$  researcher which stated that the  $IC_{50}$  value of doxorubicin for T47D cells was 250 nM. Doxorubicin has  $IC_{50}$  a low value because it has high activity against breast cancer cells [17][18].

### **Correlation Analysis of Metabolite Content with Cytotoxic Activity**

The results of the correlation analysis between metabolite profiles and cytotoxic activity shown in Table 4. Based on Table 4, the results obtained indicate that there is a significant correlation between orphenadrine levels and anticancer activity in the flower section, stem, and roots. Relationship of orphenadrine compounds with cytotoxic activity is a negative correlation. It shows a correlation in the opposite direction, where the higher the level of orphenadrine compounds, the smaller the  $IC_{50}$  value. Based on the results of these correlations, the higher the content of the compounds in the plant *C. cinerariifolium*, the higher the anticancer potential.

## **DISCUSSION**

Metabolite profiling aims to determine differences in the content of compounds in the roots, stems, leaves, and flowers of *C. cinerariifolium* and determine the characteristic compounds and major compounds with statistical analysis Principal Component Analysis (PCA). Metabolite profiling is carried out using the UPLC-QToF-MS / MS instrument that offers high resolution, speed, and sensitivity, and is effective for identifying the structure of components of natural and mixed organic compounds [19]. The findings of the compounds in the roots, stems, leaves, and flowers of *C. cinerariifolium* predicted by UPLC-QToF-MS / MS showed differences in compound content. The difference in the compound content of a part of a plant can be influenced by differences in the process of synthesizing compounds at certain stages so that a complex production of compounds occurs. The results of the profile of



the binding compounds in section *C. cinerariifolium* were then analyzed by *Principal Component Analysis* (PCA) to determine the characteristic compounds and major compounds. Identifying compounds are specific compounds that only found in parts of the organ of *C. cinerariifolium*. The compound is D - (-) - Morphine found in the flower section and N - [(5-Chloro-1,2,3-thiadiazol-4-yl) methyl] -1- (2-isopropyl-4-methyl- 1,3-thiazol-5-yl) -N-methylhexanamine and genistein in the leaf part. Further identification is a major compound which is the dominant compound with the largest percentage of area in each part. The major compounds in the flower section are D - (-) - Morphine at 10.86%, and in the roots, stems, leaves are Orphenadrine in the amount of 9.11%, 10.16%, and 3.24% respectively.

As a result of the metabolite profiling with UPLC-QToF-MS / MS, it is shown that in each part *C. cinerariifolium* contained a major compound, the compound Orphenadrine. Compound Orphenadrine is a flavonoid compound [13]. Flavonoid compounds have been reported to have antiproliferative effects on breast cancer cells and can induce cell apoptosis [17][12][19][20]. Each part of *C. cinerariifolium* is known to have different levels of compounds orphenadrine, while the compounds highest Orphenadrine found in stem part extracts of 10.16%.

The cytotoxic activity test aims to determine the differences in the anticancer cytotoxic activity of the flowers, leaves, stems, and roots of *C. cinerariifolium*. The value of anticancer cytotoxicity in each part shows different data. It is because the content of orphenadrine compounds in each section also shows different levels. In the flower section, there are 8% orphenadrine compounds, with  $IC_{50}$  T47D cells of 782.33  $\mu\text{g} / \text{mL}$ . In the leaf contains orphenadrine compounds of 2%, with  $IC_{50}$  values of 362.58  $\mu\text{g} / \text{mL}$ . In the stem contains 10.16% orphenadrine compounds with  $IC_{50}$  values of 168.46  $\mu\text{g} / \text{mL}$ . Whereas at the root part contains orphenadrine compounds of 9.11% with  $IC_{50}$  values of 293.81  $\mu\text{g} / \text{mL}$ .

Analysis of the relationship of orphenadrine compounds with anticancer cytotoxicity was carried out using Pearson correlation analysis. The results obtained showed that there was a significant correlation between the levels of orphenadrine compounds and anticancer activity in the flower, stem, and root parts, with  $P < 0.05$ . The higher the level of orphenadrine compounds, the smaller the  $IC_{50}$  value. It shows that the higher the compound content in the plant part, the greater the anticancer potential in a part of the plant.

## CONCLUSION



Flower, leaf, stem, and root extracts of *C. cinerariifolium* have different chemical content and differences in T47D cell cytotoxic activity with IC<sub>50</sub> values 682.27; 411.43; 170.94; and 286.58 µg/mL. There is a relationship between the levels of orphenadrine compounds and anticancer cytotoxic activity in each part of *C. cinerariifolium*. The higher the level of Orphenadrine compounds in the plant, the higher the potential for anticancer.

## REFERENCES

- [1] Doyle A, and Griffiths JB. (2000) Cell and Tissue Culture for Medical Research. New York: John Willey and Sons Ltd.
- [2] Keputusan Menteri Kesehatan Republik Indonesia (Kemenkes RI). (2015) Situasi Penyakit Kanker. Jakarta: Pusat Data dan Informasi.
- [3] Listiyana A, Annisa R, Suryadinata A. 2018. Efek Antikanker dan Induksi Apoptosis bunga krisan (*Chrsantemum indicum*) Herbal Tea terhadap Sel Kanker Payudara. Laporan Penelitian Lembaga Penelitian dan Pengabdian Kepada Masyarakat
- [4] Alviana, N., Sidharta, B. R. dan Martini, T. 2016. Uji Efektivitas Antibakteri Ekstrak Etanol Daun Krisan (*Chrysanthemum morifolium* Syn. *Dendrathera grandiflora*) Terhadap *Staphylococcus aureus* dan *Escherichia coli*, Yogyakarta: Universitas Atma Jaya Yogyakarta.
- [5] Boutaghane N, Voutquenne-Nazabadioko L, Simon A, *et al.* (2013) A New Triterpenic Diester from the Aerial Parts of *Chrysanthemum macrocarpum*. *Phytochemistry Letters*, 1-7.
- [6] Ukiya M, Akihisa T, Tokuda H, Suziki H, *et al* (2002) Constituents of Compositae Plants III Anti-tumor Promoting Effects and Cytotoxic Activity against Human Cancer Cell Lines of Triterpenoid Diols and Triols from Edible *Chrysanthemum* Flowers. *Cancer Letters*, 177, 7-12.
- [7] Bishayee A, Ahmed S, Brankov N, and Perloff M. (2011) Triterpenoids as Potential agents for the Chemoprevention and Therapy of Breast Cancer. *NIH Public Acces*, Vol. 12, 980-996.
- [8] Kalia R, Katnoria JK, and Nagpal AK. (2016) Antitumor Activity of Aqueous Leaf Ekstracts of Different Cultivars of *Chrysanthemum morifolium* R. Using Potato Disc Tumor Assay. *Journal of Pharmaceutical Science and Research*, Vol 8 No. 11, 1262-1265.
- [9] Jing S, Zhang X, dan Yan LJ. (2015) Antioxidant Activity, Antitumor Effect, and Antiaging Property of Proanthocyanidins Extracted from *Chrysanthemum kunlun* Flowers. *Oxidative Medicine and Cellular Longevity*, 1-10.
- [10] Muti'ah R, Hayati EK, and Triastutik Y. (2013) Pemisahan dan identifikasi Ekstrak Daun Bunga Matahari (*Helianthus annuus* L.) dengan Kromatografi Lapis Tipis. *Alchemy*, Vol. 2 No. 3, 190-194.
- [11] Harborne JB (1987) Metode Fitokimia Penuntun Cara Modern Menganalisis Tumbuhan. Bandung : ITB.
- [12] Morita R, Yafune A, Shiraki A, Itahashi M, Akane H, Nakane F, Suzuki K, Shibutani M, Mitsumori A. (2013) Enhanced Liver Tumor Promotion Activity in Rats Subjected to Combined Administration of Phenobarbital and Orphenadrine. *Journal Toxicol Science* 38(3): 415-24

- [13] Williams DH and Ian F (2013). *Metode Spektroskopi Dalam Kimia Organik*. Edisi 6. Jakarta: EGC.
- [14] Rohman A. 2014. *Statistika Dan Kemometrika Dasar Dalam Analisis Farmasi*. Dalam “Uji Kebermaknaan” Yogyakarta: Pustaka Pelajar. 95-96.
- [15] Mutiah R, Listiyana A, Indradmojo C, Griana TP, Dwi HH, Atmaja RR. (2017) Induction of Apoptosis and Phase-Cell Cycle Inhibition of G0-G1, S, G2-M of T47D Breast Cancer Cells on Treatment with Ethyl Acetate Fraction of Jackfruit Parasite Leaves (*Macrosolen cochinensis*). *Journal of Applied Pharmaceutical Science*, 07 (10): 138-143.
- [16] Costa EVS, Brigido HPC, Silva JV, *et al.* (2017) Antileishmanial Activity of *Handroanthus serratifolius* (Vahl) S. Grose (Bignoniaceae). *Evidence-Based Complementary and Alternative Medicine Hindawi*. 1-6.
- [17] Abdolmohammadi MH, Fouladdel Sh, Shafiee A, *et al* (2008) Anticancer Effects and Cell Cycle Analysis on Human Breast Cancer T47D Cells Treated with Extracts of *Astrodaucus persicus* (Boiss.) Drude in Comparison to Doxorubicin. *Journal Daru*. Vol. 16, No. 2, 112-118.
- [18] Anjarsari EY, Kristiani N, Larasati YA, *et al.* (2013) Synergistic Effect of Cinnamon Essential Oil (*Cinnamomum burmannii*) and Doxorubicin on T47D Cells Correlated with Apoptosis Induction. *Indonesian Journal of Cancer Chemoprevention*, 450-456.
- [19] Foster JS, Henley DC, Ahamed S, and Wimalasena J. (2001) Estrogens and Cell-cycle Regulation in Breast Cancer. *Trends in Endocrinology & Metabolism*, Vol. 12, 320-327.
- [20] Mutiah R, Widyawaruyanti A, Sukardiman S. 2018. *Calotropis gigantea* Leaf Extract Increases the Efficacy of 5-Fluorouracil and Decreases the Efficacy of Doxorubicin in Widr Colon Cancer Cell Culture. *Journal of Applied Pharmaceutical Science*, 8(4): 51-56.

**Table 1.** Comparison of the mobile phase system gradient

| Time (second) | % Eluent A | % Eluent B |
|---------------|------------|------------|
| 0.00          | 95.0       | 5.0        |
| 2.00          | 75.0       | 25.0       |
| 3.00          | 75.0       | 25.0       |
| 14.00         | 0.0        | 100.0      |
| 15.00         | 0.0        | 100.0      |
| 19.00         | 95.0       | 5.0        |
| 23.00         | 95.0       | 5.0        |

**Table 2.** Predicted compounds of *C.cinerariifolium*

| Ethanol 96% Extract of <i>C.cinerariifolium</i> Root |             |        |              |                |  |   |
|--|-------------|--------|--------------|----------------|--|---|
| No.  | Rt (minute) | % Area | Measured M/Z | Calculated M/Z | Formula  | Compound Name   |
| 1  | 0,723       | 0,2283 | 538,1092     | 538,1093       | C <sub>24</sub> H <sub>22</sub> N <sub>6</sub> O <sub>5</sub> S <sub>2</sub> | 3-[(2-[(4,5-Diphenyl-4H-1,2,4-triazol-3-yl)sulfanyl]acetyl}hydrazino)carbonyl]-4-methoxybenzenesulfonamide                    |
| 2  | 0,952       | 0,2600 | 171,1114     | Unknown        | Unknown  | Unknown   |
| 3  | 1,969       | 4,4400 | 202,1318     | 202,1317       | C <sub>9</sub> H <sub>18</sub> N <sub>2</sub> O <sub>3</sub>                 | Isoleucine-Alanine dipeptide  |
| 4  | 3,398       | 0,7432 | 216,0905     | 216,0906       | C <sub>5</sub> H <sub>12</sub> N <sub>8</sub> S                              | N <sup>5</sup> -[1-(5-Tetrazolidinyl)ethyl]-1,2,4-thiadiazole-3,5-diamine   |
| 5  | 3,513       | 0,1509 | 203,1158     | 203,1158       | C <sub>9</sub> H <sub>17</sub> NO <sub>4</sub>                               | L-Acetylcarnitine   |
| 6  | 3,799       | 0,1501 | 419,1785     | 419,178        | C <sub>23</sub> H <sub>25</sub> N <sub>5</sub> OS                            | 2-[(5-Ethyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)sulfanyl]-N-(1-phenylethyl)butanamide   |
| 7  | 4,164       | 1,5326 | 437,2307     | 437,2306       | C <sub>20</sub> H <sub>32</sub> N <sub>7</sub> O <sub>2</sub> Cl             | 1,3-Dimethyl-8-(1-piperidinyl)-7-[3-(3,4,5,6-tetrahydro-2-pyridinylamino)propyl]-3,7-dihydro-1H-purine-2,6-dioneHydrochloride |
| 8  | 4,645       | 1,4967 | 498,1168     | 498,1171       | C <sub>26</sub> H <sub>26</sub> O <sub>6</sub> S <sub>2</sub>                | 1,4-Phenylenebis(methylene) bis[2-methoxy-4-(methylsulfanyl)benzoate]   |
| 9  | 4,93        | 0,8488 | 516,1270     | 516,1268       | C <sub>25</sub> H <sub>24</sub> O <sub>12</sub>                              | Cynarine  |
| 10   | 5,113       | 0,0569 | 462,1164     | 462,1162       | C <sub>22</sub> H <sub>22</sub> O <sub>11</sub>                              | 2,2'-[(3,4,5-   |

|    |        |        |          |          |  |   |
|----|--------|--------|----------|----------|--|---|
|    |        |        |          |          |  | Trimethoxyphenyl)methylene] bis[3-hydroxy-6-(hydroxymethyl)-4H-pyran-4-one]   |
| 11 | 5,296  | 0,0534 | 678,1586 | 678,1585 | C <sub>34</sub> H <sub>30</sub> O <sub>15</sub>                  | (3R,5R)-3,4,5-Tris{[(2E)-3-(3,4-dihydroxyphenyl)-2-propenoyl]oxy}-1-hydroxycyclohexanecarboxylic acid   |
| 12 | 5,411  | 0,0143 | 505,2147 | 505,2148 | C <sub>27</sub> H <sub>31</sub> N <sub>5</sub> O <sub>3</sub> S  | 2-{Benzyl[2,2-dimethyl-5-(4-morpholinyl)1,4-dihydro-2H-pyran-4",3":4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-8-yl]amino}ethanol                                 |
| 13 | 5,628  | 0,0879 | 518,1054 | 518,1049 | C <sub>29</sub> H <sub>18</sub> N <sub>4</sub> O <sub>4</sub> S  | N'-[(2E)-5-[(3-Oxo-3H-benzof]chromen-2-yl)carbonyl]-3-phenyl-1,3,4-thiadiazol-2(3H)-ylidene]benzohydrazide  |
| 14 | 5,776  | 0,0297 | 358,1893 | 358,1893 | C <sub>20</sub> H <sub>26</sub> N <sub>2</sub> O <sub>4</sub>    | Itopride  |
| 15 | 5,891  | 0,0408 | 194,0943 | 194,0943 | C <sub>11</sub> H <sub>14</sub> O <sub>3</sub>                   | Butylparaben  |
| 16 | 6,142  | 0,0825 | 213,1524 | Unknown  | H15N13O  | Unknown   |
| 17 | 6,257  | 0,0368 | 678,1592 | Unknown  | C <sub>25</sub> H <sub>18</sub> N <sub>20</sub> O <sub>3</sub> S | Unknown   |
| 18 | 6,36   | 0,0264 | 592,1793 | 592,1792 | C <sub>28</sub> H <sub>32</sub> O <sub>14</sub>                  | Acaciin   |
| 19 | 6,691  | 0,1132 | 460,1000 | 460,0999 | C <sub>14</sub> H <sub>24</sub> N <sub>2</sub> O <sub>13</sub> S | (2S,3R,4R,5S)-3-[(2-Acetamido-2-deoxy-6-O-sulfo- $\alpha$ -D-glucopyranosyl)oxy]-4,5-dihydroxy-2-piperidinecarboxylic acid  |
| 20 | 6,76   | 0,0963 | 241,1167 | 241,1678 | C <sub>13</sub> H <sub>23</sub> NO <sub>3</sub>                  | 2-Methyl-2-propanyl 2-isopropyl-4-oxo-1-piperidinecarboxylate   |
| 21 | 6,908  | 0,0758 | 296,2143 | 296,2140 | C <sub>21</sub> H <sub>28</sub> O                                | Pregna-1,4,20-trien-3-one   |
| 22 | 7,171  | 0,1858 | 411,3136 | 412,3214 | C <sub>27</sub> H <sub>41</sub> NO <sub>2</sub>                  | Cyclopamine   |
| 23 | 7,72   | 0,6027 | 445,2108 | 445,2107 | C <sub>17</sub> H <sub>31</sub> N <sub>7</sub> O <sub>5</sub> S  | Alanylarginylcysteinylproline   |
| 24 | 7,903  | 0,6371 | 589,2517 | 589,2518 | C <sub>43</sub> H <sub>31</sub> N <sub>3</sub>                   | 3,3',3"-Methanetriyltris(2-phenyl-1H-indole)  |
| 25 | 8,52   | 1,1771 | 230,0951 | 230,0950 | C <sub>7</sub> H <sub>14</sub> N <sub>6</sub> OS                 | 3-{2-[(3-Amino-1,2,4-thiadiazol-5-yl)amino]ethyl}-1,1-dimethylurea  |
| 26 | 8,852  | 0,7089 | 439,3814 | 439,3814 | C <sub>30</sub> H <sub>49</sub> NO                               | (1R,6aR,8S,10aS,12aR)-7,7,10a,12a-Tetramethyl-1-[(2R)-6-methyl-5-methylene-2-heptanyl]1,2,3,5,6,6a,7,8,9,10,10a,11,12,12a-tetradecahydronaphtho[1,2-h]quinolin-8-ol |
| 27 | 9,138  | 2,0262 | 326,1518 | 326,1518 | C <sub>20</sub> H <sub>22</sub> O <sub>4</sub>                   | Dentatin  |
| 28 | 9,367  | 1,5253 | 469,2615 | 469,2617 | C <sub>31</sub> H <sub>35</sub> NO <sub>3</sub>                  | Cyclohexyl 4-(4-ethylphenyl)-2-methyl-5-oxo-7-phenyl-1,4,5,6,7,8-hexahydro-3-Quinolinecarboxylate   |
| 29 | 9,469  | 0,8146 | 267,1628 | Unknown  | C <sub>3</sub> H <sub>17</sub> N <sub>13</sub> O <sub>2</sub>    | Unknown   |
| 30 | 9,835  | 0,8792 | 770,3297 | Unknown  | C <sub>57</sub> H <sub>42</sub> N <sub>2</sub> O                 | Unknown   |
| 31 | 10,167 | 0,8157 | 293,2366 | Unknown  | C <sub>11</sub> H <sub>31</sub> N <sub>7</sub> S                 | Unknown   |
| 32 | 10,418 | 1,4244 | 544,2116 | 544,2117 | C <sub>26</sub> H <sub>28</sub> N <sub>10</sub> O <sub>2</sub> S | 3-Methyl-8-(4-phenyl-1-piperazinyl)-7-{3-[(1-phenyl-1H-tetrazol-5-yl)sulfanyl]propyl}-3,7-dihydro-1H-purine-2,6-dione   |
| 33 | 10,933 | 9,1093 | 269,1783 | 269,1780 | C <sub>18</sub> H <sub>23</sub> NO                               | Orphenadrine  |
| 34 | 11,413 | 0,7639 | 273,2099 | Unknown  | C <sub>3</sub> H <sub>23</sub> N <sub>13</sub> O <sub>2</sub>    | Unknown   |

|   |        |        |          |          |   |  |
|---|--------|--------|----------|----------|---|--|
| 35  | 11,596 | 0,9682 | 208,1108 | Unknown  | C <sub>5</sub> H <sub>16</sub> N <sub>6</sub> OS                              | Unknown  |
| 36  | 11,848 | 0,3086 | 212,0837 | 212,0837 | C <sub>14</sub> H <sub>12</sub> O <sub>2</sub>                                | Benzoin  |
| 37  | 11,996 | 0,2354 | 276,2097 | Unknown  | C <sub>11</sub> H <sub>29</sub> N <sub>6</sub> S                              | Unknown  |
| 38  | 12,179 | 6,6129 | 275,2253 | 275,2249 | C <sub>18</sub> H <sub>29</sub> NO  | 1,3,5-Tris(2-methyl-2-propanyl)-2-nitrosobenzene   |
| 39  | 12,396 | 0,5288 | 251,2258 | Unknown  | Unknown   | Unknown  |
| 40  | 12,545 | 0,0684 | 322,1210 | 322,1212 | C <sub>13</sub> H <sub>18</sub> N <sub>6</sub> O <sub>2</sub> S               | N-(2-Cyano-3-methyl-2-butanyl)-5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine-2-sulfonamide              |
| 41  | 12,694 | 0,4986 | 323,2252 | 323,2249 | C <sub>22</sub> H <sub>29</sub> NO  | (E)-1-(4-Butoxyphenyl)-N-(4-pentylphenyl)methanimine   |
| 42  | 12,945 | 7,0016 | 277,2413 | Unknown  | Unknown   | Unknown  |
| 43  | 13,391 | 0,3227 | 291,2566 | 291,2562 | C <sub>19</sub> H <sub>33</sub> NO  | 4-[(Diethylamino)methyl]-2,6-bis(2-methyl-2-propanyl)phenol  |
| 44  | 13,791 | 4,4868 | 279,2567 | 279,2562 | C <sub>18</sub> H <sub>33</sub> NO  | Linoleamide  |
| 45  | 14,157 | 3,9045 | 281,2720 | 281,2719 | C <sub>18</sub> H <sub>35</sub> NO  | (9Z)-9-Octadecenimidic Acid  |
| <b>Ethanol 96% Extract of <i>C.cinerariifolium</i> Stem</b> |        |        |          |          |   |  |
| 1   | 0,62   | 0,1715 | 174,1121 | 190,1066 | C <sub>6</sub> H <sub>14</sub> N <sub>4</sub> O <sub>3</sub>                  | 4-Hydroxyarginine  |
| 2   | 0,837  | 0,0022 | 103,1000 | 103,0977 | C <sub>5</sub> H <sub>13</sub> NO   | L-(+)-Valinol  |
| 3   | 1,42   | 1,4998 | 119,9735 | 119,0735 | C <sub>8</sub> H <sub>9</sub> N   | Indoline   |
| 4   | 1,901  | 1,6853 | 202,1321 | 202,1317 | C <sub>9</sub> H <sub>18</sub> N <sub>2</sub> O <sub>3</sub>                  | Isoleucine-Alanine dipeptide   |
| 5   | 2,266  | 0,0741 | 187,0634 | 187,0633 | C <sub>11</sub> H <sub>9</sub> NO <sub>2</sub>                                | Indoleacrylic acid   |
| 6   | 2,449  | 0,0478 | 315,1691 | 315,1691 | C <sub>16</sub> H <sub>29</sub> NOS <sub>2</sub>                              | N-[2-(1-Cyclohexen-1-yl)ethyl]-4,4-bis(ethylsulfanyl)butanamide  |
| 7   | 3,364  | 0,3949 | 217,0980 | 216,0899 | C <sub>12</sub> H <sub>12</sub> N <sub>2</sub> O <sub>2</sub>                 | 3',4'-Dihydro-1'H,2H,5H-spiro[imidazolidine-4,2'-naphthalene]-2,5-dione                                |
| 8   | 3,696  | 0,3654 | 441,2626 | 441,2628 | C <sub>25</sub> H <sub>35</sub> N <sub>3</sub> O <sub>4</sub>                 | N-{4-[(3-Methoxy-4-{2-[(2-methyl-2-propanyl)amino]-2-oxoethoxybenzyl)amino]phenyl}-3-methylbutanamide  |
| 9   | 3,947  | 0,7645 | 439,2471 | 439,2471 | C <sub>25</sub> H <sub>33</sub> N <sub>3</sub> O <sub>4</sub>                 | N-Isobutyl-N <sup>2</sup> -{2-[(4-methoxybenzoyl)amino]benzoyl}isoleucinamide                          |
| 10  | 4,096  | 0,2378 | 439,2478 | 439,2481 | C <sub>19</sub> H <sub>39</sub> N <sub>5</sub> O <sub>2</sub> Cl <sub>2</sub> | N-(2-{4-[2-(2,5-Dimethyl-1-pyrrolidinyl)ethyl]-1-piperazinyl}-2-oxoethyl)-L-valinamide dihydrochloride |
| 11  | 4,347  | 0,2550 | 462,0811 | 462,0812 | C <sub>22</sub> H <sub>14</sub> N <sub>4</sub> O <sub>8</sub>                 | 2,5,7-Trinitro-9-oxo-N-(1-phenylethyl)-9H-fluorene-4-carboxamide                                       |
| 12  | 4,862  | 0,9273 | 432,1064 | 432,1063 | C <sub>14</sub> H <sub>20</sub> N <sub>6</sub> O <sub>8</sub> S               | L-γ-Glutamyl-S-(1-methyl-4-nitro-1H-imidazol-5-yl)-L-cysteinylglycine                                  |
| 13  | 5,079  | 0,2746 | 462,1171 | 462,1171 | C <sub>23</sub> H <sub>26</sub> O <sub>6</sub> S <sub>2</sub>                 | Bicyclo[2.2.1]hept-5-ene-2,3-diylbis(methylene)bis(4-methylbenzenesulfonate)                           |
| 14  | 5,479  | 0,1150 | 337,2608 | Unknown  | C <sub>15</sub> H <sub>36</sub> N <sub>5</sub> OCl                            | Unknown  |
| 15  | 5,811  | 0,0544 | 225,1368 | 225,1365 | C <sub>12</sub> H <sub>19</sub> NO <sub>3</sub>                               | Terbutaline  |
| 16  | 5,959  | 0,0349 | 286,0467 | 286,0464 | C <sub>12</sub> H <sub>2</sub> N <sub>10</sub>                                | 2,2'-[1,2,3]Triazolo[4,5-f]benzotriazole-4,8(2H,6H)-diylidenedimalononitrile                           |

|    |        |         |          |          |   |  |
|----|--------|---------|----------|----------|---|--|
| 17 | 6,074  | 0,1311  | 287,0478 | 286,0477 | C <sub>15</sub> H <sub>10</sub> O <sub>6</sub>                              | Kaempferol   |
| 18 | 6,325  | 0,0370  | 592,1804 | 592,1805 | C <sub>29</sub> H <sub>28</sub> N <sub>4</sub> O <sub>10</sub>              | 6-[(1,3-Dihydroxy-2-propylamino)-12-(D-glucopyranosyl)-2-hydroxy-12,13-dihydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione   |
| 19 | 6,84   | 0,7766  | 270,0532 | 270,0503 | C <sub>8</sub> H <sub>18</sub> N <sub>2</sub> O <sub>2</sub> S <sub>3</sub> | Methyl {2-[(2-methyl-2-propyl)sulfamoyl]ethyl} carbamodithioate  |
| 20 | 7,057  | 0,1229  | 300,0638 | 300,0639 | C <sub>12</sub> H <sub>9</sub> N <sub>8</sub> Cl                            | 4-Chloro-2-[(6-hydrazino-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzotrile   |
| 21 | 7,24   | 0,3950  | 330,0737 | 330,0740 | C <sub>17</sub> H <sub>14</sub> O <sub>7</sub>                              | Rhamnazin  |
| 22 | 7,491  | 0,2355  | 192,0787 | 192,0786 | C <sub>11</sub> H <sub>12</sub> O <sub>3</sub>                              | Myristicin   |
| 23 | 7,972  | 0,4806  | 471,2268 | 471,2270 | C <sub>27</sub> H <sub>29</sub> N <sub>5</sub> O <sub>3</sub>               | Ethyl 4-[7-(4-ethoxyphenyl)-5-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-1-piperazinecarboxylate  |
| 24 | 8,12   | 0,0976  | 487,2585 | 487,2583 | C <sub>28</sub> H <sub>33</sub> N <sub>5</sub> O <sub>3</sub>               | 8-[2-(Adamantan-1-yl)ethyl]-7-(4-methoxyphenyl)-1,3-dimethyl-1H-imidazo[2,1-f]purine-2,4(3H,8H)-dione  |
| 25 | 8,521  | 0,4004  | 521,2416 | 521,2414 | C <sub>30</sub> H <sub>35</sub> NO <sub>7</sub>                             | 2-Phenoxyethyl 2,7,7-trimethyl-5-oxo-4-(2,3,4-trimethoxyphenyl)-1,4,5,6,7,8-hexahydro-3-quinolinecarboxylate   |
| 26 | 8,635  | 0,0150  | 290,1885 | 290,1882 | C <sub>18</sub> H <sub>26</sub> O <sub>3</sub>                              | Octyl methoxycinnamate   |
| 27 | 9,184  | 2,5971  | 229,1470 | 229,1467 | C <sub>15</sub> H <sub>19</sub> NO  | pronetalol   |
| 28 | 9,401  | 0,1554  | 368,1257 | 368,1260 | C <sub>21</sub> H <sub>20</sub> O <sub>6</sub>                              | Curcumin   |
| 29 | 9,835  | 1,1838  | 770,3275 | 770,3275 | C <sub>40</sub> H <sub>46</sub> N <sub>6</sub> O <sub>10</sub>              | 2-(1,3-Benzodioxol-5-yl)-N[(6S,10S,12S,15S,18S)-6-benzyl-15-[(1R)-1-hydroxyethyl]-18-methyl-4,7,13,16,19-penta-oxo-2-oxa-5,8,14,17,20-pentaazatricyclo[21.2.2.0 <sup>8,12</sup> ]heptacos-1(25),23,26-trien-10-yl] acetamide |
| 30 | 10,098 | 0,4848  | 315,2780 | Unknown  | Unknown   | Unknown  |
| 31 | 10,236 | 0,1737  | 303,2209 | Unknown  | Unknown   | Unknown  |
| 32 | 10,899 | 10,1668 | 269,1784 | 269,1780 | C <sub>18</sub> H <sub>23</sub> NO  | Orphenadrine   |
| 33 | 11,379 | 1,2072  | 285,2093 | 285,2093 | C <sub>19</sub> H <sub>27</sub> NO  | (R)-Pentazocine  |
| 34 | 11,596 | 1,0216  | 208,1098 | 208,1099 | C <sub>12</sub> H <sub>16</sub> O <sub>3</sub>                              | Asarone  |
| 35 | 11,813 | 0,1758  | 297,2094 | 297,2093 | C <sub>20</sub> H <sub>27</sub> NO  | Butaminophen   |
| 36 | 11,996 | 0,2293  | 365,3268 | Unknown  | Unknown   | Unknown  |
| 37 | 12,145 | 3,9746  | 275,2245 | 275,2249 | C <sub>18</sub> H <sub>29</sub> NO  | 1,3,5-Tris(2-methyl-2-propyl)-2-nitrosobenzene   |
| 38 | 12,476 | 0,5490  | 341,3300 | Unknown  | Unknown   | Unknown  |
| 39 | 12,694 | 0,3503  | 323,2254 | 323,2249 | C <sub>22</sub> H <sub>29</sub> NO  | p-butoxybenzylidene p-pentylaniline  |
| 40 | 12,911 | 4,1215  | 277,2408 | 277,2406 | C <sub>18</sub> H <sub>31</sub> NO  | 4-(Dodecyloxy)aniline  |
| 41 | 13,208 | 0,0798  | 392,2319 | 392,2320 | C <sub>22</sub> H <sub>36</sub> N <sub>2</sub> S <sub>2</sub>               | [(Tetradecylamino)methyl]-1,3-benzothiazole-2(3H)-thione   |

|   |        |        |          |          |   |   |
|---|--------|--------|----------|----------|---|---|
| 42  | 13,494 | 0,1143 | 267,2566 | 267,2562 | C <sub>17</sub> H <sub>33</sub> NO  | Hexadecyl isocyanate  |
| 43  | 13,757 | 1,5396 | 279,2571 | Unknown  | Unknown   | Unknown   |
| 44  | 14,157 | 3,3119 | 281,2723 | 281,2719 | C <sub>18</sub> H <sub>35</sub> NO  | Oleamide  |
| 45  | 14,374 | 1,458  | 293,2732 | Unknown  | Unknown   | Unknown   |
| 46  | 14,706 | 0,1309 | 295,2874 | 295,2875 | C <sub>19</sub> H <sub>37</sub> NO  | 1-Isocyanatooctadecane  |
| 47  | 15,106 | 0,1145 | 333,3027 | 333,3032 | C <sub>22</sub> H <sub>39</sub> NO  | p-Hexadecyloxyaniline   |
| 48  | 15,289 | 1,3600 | 309,3030 | 309,3032 | C <sub>20</sub> H <sub>39</sub> NO  | 1-Hexadecanoylpyrrolidine   |
| 49  | 15,472 | 0,0141 | 610,4597 | 610,4597 | C <sub>39</sub> H <sub>62</sub> O <sub>5</sub>                                  | [1-(2-{{(3β)-3-Hydroxylup-20(29)-en-28-yl}oxy)-2-oxoethyl}cyclopentyl]acetic acid   |
| 50  | 15,586 | 0,2357 | 311,3198 | Unknown  | Unknown   | Unknown   |
| 51  | 16,204 | 0,2967 | 493,5588 | 493,5587 | C <sub>34</sub> H <sub>71</sub> N   | N-Hexadecyl-1-octadecanamine  |
| 52  | 16,604 | 0,7435 | 521,5911 | Unknown  | CH <sub>2</sub> N <sub>2</sub> O <sub>3</sub> S <sub>5</sub> ClBr <sub>3</sub>  | Unknown   |
| <b>Ethanol 96% Extract of <i>C.cinerariifolium</i> Leaf</b> |        |        |          |          |   |   |
| 1   | 0,586  | 0,0837 | 150,0280 | 150,0277 | C <sub>3</sub> H <sub>6</sub> N <sub>2</sub> O <sub>5</sub>                     | Urea ethanedioate   |
| 2   | 0,769  | 0,0398 | 292,0567 | 292,0565 | C <sub>11</sub> H <sub>12</sub> N <sub>6</sub> S <sub>2</sub>                   | 9-Methyl-5-(methylsulfanyl)-8,9,10,11-tetrahydropyrido[4',3':4,5]hieno[3,2-e]tetrazolo[1,5-c]pyrimidine                                     |
| 3   | 1,42   | 1,0781 | 119,0735 | 119,0735 | C <sub>8</sub> H <sub>9</sub> N   | Indoline  |
| 4   | 1,935  | 0,1100 | 202,1318 | 202,1317 | C <sub>9</sub> H <sub>18</sub> N <sub>2</sub> O <sub>3</sub>                    | Isoleucyl-Alanine   |
| 5   | 2,266  | 0,7538 | 187,0634 | 187,0633 | C <sub>11</sub> H <sub>9</sub> NO <sub>2</sub>                                  | Indoleacrylic acid  |
| 6   | 2,518  | 0,0526 | 185,1163 | 185,1164 | C <sub>8</sub> H <sub>15</sub> N <sub>3</sub> O <sub>2</sub>                    | 1-Acetyl-3-piperidinecarbohydrazide   |
| 7   | 3,364  | 0,2818 | 216,0902 | 216,0899 | C <sub>12</sub> H <sub>12</sub> N <sub>2</sub> O <sub>2</sub>                   | 3',4'-Dihydro-1'H,2H,5H-spiro[imidazolidine-4,2'-naphthalene]-2,5-dione   |
| 8   | 3,764  | 0,3684 | 243,1474 | 243,1471 | C <sub>12</sub> H <sub>21</sub> NO <sub>4</sub>                                 | Tiglylcarnitine   |
| 9   | 3,947  | 0,3261 | 439,2475 | 439,2471 | C <sub>25</sub> H <sub>33</sub> N <sub>3</sub> O <sub>4</sub>                   | N-Isobutyl-N <sup>2</sup> -{2-[(4-methoxybenzoyl)amino]benzoyl}isoleucinamide   |
| 10  | 4,347  | 0,1707 | 462,0800 | 462,0798 | C <sub>17</sub> H <sub>23</sub> N <sub>4</sub> O <sub>5</sub> S <sub>2</sub> Cl | 4-Chloro-2-({4-[(2,6-dimethyl-4-morpholinyl)sulfonyl]-1-piperazinyl)sulfonyl}benzotrile   |
| 11  | 4,645  | 0,1249 | 578,1638 | 578,1636 | C <sub>27</sub> H <sub>30</sub> O <sub>14</sub>                                 | Kaempferitrin   |
| 12  | 4,862  | 0,5915 | 446,0862 | 446,0862 | C <sub>22</sub> H <sub>14</sub> N <sub>4</sub> O <sub>7</sub>                   | N-[(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-3,5-dinitro-N-phenylbenzamide  |
| 13  | 5,262  | 0,0129 | 349,2245 | Unknown  | C <sub>15</sub> H <sub>32</sub> N <sub>5</sub> O <sub>2</sub> Cl                | Unknown   |
| 14  | 5,662  | 0,0720 | 527,1920 | 527,1922 | C <sub>25</sub> H <sub>34</sub> NO <sub>9</sub> Cl                              | 1-(Nitrooxy)-2-propanyl(5Z)-7-{{(1R,2R,3R,5S)-2-[(1E,3R)-4-(3-chlorophenoxy)-3-hydroxy-1-buten-1-yl]-3,5-dihydroxycyclopentyl}-5-heptenoate |
| 15  | 5,776  | 0,1556 | 459,2259 | 459,2257 | C <sub>25</sub> H <sub>33</sub> NO <sub>7</sub>                                 | 2-Methoxyethyl 2,7,7-trimethyl-5-oxo-4-(3,4,5-trimethoxyphenyl)-1,4,5,6,7,8-hexahydro-3-quinolinecarboxylate                                |
| 16  | 6,074  | 0,2245 | 286,0479 | 286,0477 | C <sub>15</sub> H <sub>10</sub> O <sub>6</sub>                                  | Kaempferol  |
| 17  | 6,257  | 0,1001 | 316,0585 | 316,0583 | C <sub>16</sub> H <sub>12</sub> O <sub>7</sub>                                  | Isorhamnetin  |
| 18  | 6,84   | 1,7179 | 270,0533 | 270,0528 | C <sub>15</sub> H <sub>10</sub> O <sub>5</sub>                                  | Genistein   |
| 19  | 7,274  | 1,8113 | 330,0737 | 330,0740 | C <sub>13</sub> H <sub>19</sub> N <sub>4</sub> S <sub>2</sub> Cl                | N-[(5-Chloro-1,2,3-thiadiazol-4-yl)methyl]-1-   |



|  |        |        |          |          |   |  |
|--|--------|--------|----------|----------|---|--|
|  |        |        |          |          |   | (2-isopropyl-4-methyl-1,3-thiazol-5-yl)-N-methylethanamine   |
| 20   | 7,572  | 0,0101 | 488,2162 | 488,2159 | C <sub>25</sub> H <sub>32</sub> N <sub>2</sub> O <sub>8</sub>               | (2-Methyl-1,4-piperazinediyl)bis[(3,4,5-trimethoxyphenyl)methanone]  |
| 21   | 7,674  | 0,0150 | 309,2302 | 309,2304 | C <sub>18</sub> H <sub>31</sub> NO <sub>3</sub>                             | N,N-Diisobutyl-4,7,7-trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1-carboxamide                                  |
| 22   | 7,972  | 0,2336 | 471,2255 | 471,2257 | C <sub>26</sub> H <sub>33</sub> NO <sub>7</sub>                             | 2-Methoxyethyl 4-(4-acetoxy-3-ethoxyphenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydro-3-quinolinecarboxylate |
| 23   | 8,223  | 0,0365 | 344,0906 | 344,0905 | C <sub>19</sub> H <sub>20</sub> O <sub>2</sub> S <sub>2</sub>               | 2-(7,8-Dimethyl-1,5-dihydro-2,4-benzodithiepin-3-yl)phenyl acetate   |
| 24   | 8,406  | 0,0689 | 234,1627 | Unknown  | C <sub>8</sub> H <sub>22</sub> N <sub>6</sub> S                             | Unknown  |
| 25   | 8,52   | 0,0225 | 521,2415 | 521,2414 | C <sub>30</sub> H <sub>35</sub> NO <sub>7</sub>                             | 2-Phenoxyethyl 2,7,7-trimethyl-5-oxo-4-(2,3,4-trimethoxyphenyl)-1,4,5,6,7,8-hexahydro-3-quinolinecarboxylate   |
| 26   | 9,138  | 0,4170 | 229,1472 | 229,1467 | C <sub>15</sub> H <sub>19</sub> NO  | Pronetalolol   |
| 27   | 9,652  | 0,0098 | 403,1164 | 403,1168 | C <sub>22</sub> H <sub>17</sub> N <sub>3</sub> O <sub>5</sub>               | Azoxystrobin   |
| 28   | 10,235 | 0,1533 | 218,1672 | 218,1671 | C <sub>15</sub> H <sub>22</sub> O   | (+)-Nootkatone   |
| 29   | 10,716 | 0,5352 | 267,1622 | 267,1623 | C <sub>18</sub> H <sub>21</sub> NO  | Azacyclonol  |
| 30   | 10,899 | 3,2354 | 269,1780 | 269,1780 | C <sub>18</sub> H <sub>23</sub> NO  | Orphenadrine   |
| 31   | 11,379 | 0,5113 | 387,0986 | 387,0986 | C <sub>19</sub> H <sub>18</sub> N <sub>3</sub> O <sub>4</sub> Cl            | Pyraclostrobin   |
| 32   | 11,596 | 0,1104 | 519,3324 | 519,3322 | C <sub>29</sub> H <sub>41</sub> N <sub>7</sub> O <sub>2</sub>               | 3-[(4-Cyclohexyl-1-piperazinyl)(1-cyclohexyl-1H-tetrazol-5-yl)methyl]-6-ethoxy-2(1H)-quinolinone               |
| 33   | 12,145 | 1,0840 | 275,2257 | Unknown  | Unknown   | Unknown  |
| <b>Ethanol 96% Extract of <i>C. cinerariifolium</i> Flower</b> |        |        |          |          |   |  |
| 1  | 0,62   | 0,2307 | 174,1122 | 174,1117 | C <sub>6</sub> H <sub>14</sub> N <sub>4</sub> O <sub>2</sub>                | L-Arginine   |
| 2  | 1,42   | 1,5649 | 119,0736 | 119,0735 | C <sub>8</sub> H <sub>9</sub> N   | Indoline   |
| 3  | 1,901  | 1,9443 | 202,1319 | 202,1317 | C <sub>9</sub> H <sub>18</sub> N <sub>2</sub> O <sub>3</sub>                | Isoleucine-Alanine dipeptide   |
| 4  | 2,266  | 2,1291 | 187,0639 | 187,0633 | C <sub>11</sub> H <sub>9</sub> NO <sub>2</sub>                              | Indoleacrylic acid   |
| 5  | 3,364  | 0,5735 | 441,2623 | 441,2628 | C <sub>25</sub> H <sub>35</sub> N <sub>3</sub> O <sub>4</sub>               | N-{4-[(3-Methoxy-4-{2-[(2-methyl-2-propanyl)amino]-2-oxoethoxy}benzyl)amino]phenyl}-3-methylbutanamide         |
| 6  | 3,947  | 1,5082 | 439,2469 | 439,2471 | C <sub>25</sub> H <sub>33</sub> N <sub>3</sub> O <sub>4</sub>               | N-Isobutyl-N <sup>2</sup> -{2-[(4-methoxybenzoyl)amino]benzoyl} isoleucinamide                                 |
| 7  | 4,862  | 3,7310 | 432,1057 | 432,1056 | C <sub>21</sub> H <sub>20</sub> O <sub>10</sub>                             | 5-Hydroxy-3-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl hexopyranoside   |
| 8  | 5,479  | 1,9686 | 640,3257 | 640,3254 | C <sub>29</sub> H <sub>48</sub> N <sub>6</sub> O <sub>8</sub> S             | L-Lysyl-L-leucyl-L-methionyl-L-seryl-L-tyrosine  |
| 9  | 5,959  | 2,1848 | 286,0490 | 286,0486 | C <sub>16</sub> H <sub>14</sub> OS <sub>2</sub>                             | (2Z,6E)-2,6-Bis(2-thienylmethylene)cyclohexanone   |
| 10   | 6,108  | 1,962  | 286,0480 | 286,0480 | C <sub>8</sub> H <sub>18</sub> N <sub>2</sub> O <sub>3</sub> S <sub>3</sub> | 2-   |

|    |        |         |          |          |   |  |
|----|--------|---------|----------|----------|---|--|
|    |        |         |          |          |   | {[3(Methylsulfinyl)propyl] sulfamoyl]butanethioamide   |
| 11 | 6,325  | 0,1416  | 592,1790 | 592,1792 | C <sub>28</sub> H <sub>32</sub> O <sub>14</sub>                             | Acaciin  |
| 12 | 6,394  | 0,0817  | 474,1152 | 474,1150 | C <sub>28</sub> H <sub>18</sub> N <sub>4</sub> O <sub>2</sub> S             | 3-(4-Methylbenzoyl)-2-(4-phenyl-2-thioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)-1-benzofuran-5,6-dicarbonitrile         |
| 13 | 6,84   | 3,1285  | 270,0531 | 270,0530 | C <sub>8</sub> H <sub>18</sub> N <sub>2</sub> O <sub>2</sub> S <sub>3</sub> | Methyl {2-[(2-methyl-2-propanyl)sulfamoyl]ethyl} Carbamodithioate  |
| 14 | 7,24   | 1,5010  | 360,0846 | 360,0845 | C <sub>18</sub> H <sub>16</sub> O <sub>8</sub>                              | (R)-(+)-rosmarinic acid  |
| 15 | 7,572  | 0,1700  | 488,2156 | 488,2159 | C <sub>25</sub> H <sub>32</sub> N <sub>2</sub> O <sub>8</sub>               | (2-Methyl-1,4-piperazinediyl)bis[(3,4,5-trimethoxyphenyl)methanone]  |
| 16 | 7,972  | 1,0043  | 471,2262 | 471,2262 | C <sub>22</sub> H <sub>30</sub> N <sub>9</sub> OCl                          | N-{2-[(7-Chloro-4-quinolinyl)amino]ethyl}-N'-[2-(dimethylamino)ethyl]-6-(4-morpholinyl)-1,3,5-triazine-2,4-diamine |
| 17 | 8,223  | 0,6838  | 344,0897 | 344,0896 | C <sub>18</sub> H <sub>16</sub> O <sub>7</sub>                              | (±)-Usnic acid   |
| 18 | 8,406  | 0,3363  | 271,1210 | 271,1208 | C <sub>16</sub> H <sub>17</sub> NO <sub>3</sub>                             | O-Benzyl-L-tyrosine  |
| 19 | 8,669  | 0,1494  | 284,0687 | 284,0687 | C <sub>9</sub> H <sub>20</sub> N <sub>2</sub> O <sub>2</sub> S <sub>3</sub> | (3-Methyl-1,1-dioxidotetrahydro-3-thiophenyl)carbamodithioic acid-N,N-dimethylmethanamine                          |
| 20 | 9,401  | 10,8649 | 285,1367 | 285,1265 | C <sub>17</sub> H <sub>19</sub> NO <sub>3</sub>                             | D-(-)-Morphine   |
| 21 | 9,584  | 6,7201  | 285,1375 | 285,1375 | C <sub>11</sub> H <sub>25</sub> N <sub>3</sub> OCl <sub>2</sub>             | 2-[4-(4-Piperidinyl)-1-piperazinyl] ethanol Dihydrochloride  |
| 22 | 9,835  | 0,3062  | 277,1473 | Unknown  | C <sub>4</sub> H <sub>15</sub> N <sub>13</sub> O <sub>2</sub>               | Unknown  |
| 23 | 9,984  | 0,0280  | 291,2200 | 291,2198 | C <sub>18</sub> H <sub>29</sub> NO <sub>2</sub>                             | 1-(2-Cyclopentylphenoxy)-3-[(2-methyl-2-propanyl)amino]-2-propanol   |
| 24 | 10,281 | 3,4908  | 311,1524 | 311,1521 | C <sub>19</sub> H <sub>21</sub> NO <sub>3</sub>                             | Nalorphine   |
| 25 | 10,75  | 2,8304  | 267,1624 | 267,1263 | C <sub>18</sub> H <sub>21</sub> NO  | Azacyclonol  |
| 26 | 10,899 | 8,6205  | 269,1785 | 269,1780 | C <sub>18</sub> H <sub>23</sub> NO  | Orphenadrine   |
| 27 | 11,264 | 1,8554  | 339,1833 | 339,1834 | C <sub>21</sub> H <sub>25</sub> NO <sub>3</sub>                             | Pipethanate  |
| 28 | 11,413 | 2,5239  | 285,2094 | 285,2093 | C <sub>19</sub> H <sub>27</sub> NO  | (R)-Pentazocine  |
| 29 | 11,596 | 0,7026  | 519,3323 | 519,3322 | C <sub>29</sub> H <sub>41</sub> N <sub>7</sub> O <sub>2</sub>               | 3-[(4-Cyclohexyl-1-piperazinyl)(1-cyclohexyl-1H-tetrazol-5-yl)methyl]-6-ethoxy-2(1H)-quinolinone                   |
| 30 | 11,962 | 3,1903  | 343,2147 | 343,2147 | C <sub>21</sub> H <sub>29</sub> NO <sub>3</sub>                             | Smenospongine  |
| 31 | 12,179 | 4,9042  | 275,2253 | 275,2259 | C <sub>18</sub> H <sub>29</sub> NO  | 1,3,5-Tris(2-methyl-2-propanyl)-2-nitrosobenzene   |
| 32 | 12,396 | 0,5785  | 251,2252 | 251,2249 | C <sub>16</sub> H <sub>29</sub> NO  | (6Z,8S,8aS)-8-Methyl-6-[(2R)-2-methylhexylidene]octahydro-8-indolizinol  |
| 33 | 12,694 | 1,1111  | 323,2249 | 323,2249 | C <sub>22</sub> H <sub>29</sub> NO  | (E)-1-(4-Butoxyphenyl)-N-(4-pentylphenyl)methanimine   |
| 34 | 12,911 | 4,6764  | 277,2411 | 277,2406 | C <sub>18</sub> H <sub>31</sub> NO  | 4-(Dodecyloxy)aniline  |
| 35 | 13,345 | 0,0842  | 602,5275 | 602,5274 | C <sub>39</sub> H <sub>70</sub> O <sub>4</sub>                              | (2S)-1-(Hexadecyloxy)-3-hydroxy-2-propanyl 5,8,11,14-icosatetraenoate  |
| 36 | 13,757 | 1,3846  | 279,2566 | 279,2562 | C <sub>18</sub> H <sub>33</sub> NO  | Linoleamide  |

**Table 3.** IC<sub>50</sub> value of T47D cell line after treatment with *C. cinerariifolium*


| Sample      | IC <sub>50</sub> T47D cell line ± SD (%) <sup>*</sup> |
|-------------|---|
| Flower      | 782,33 µg/mL ± 13,98                                  |
| Leave       | 362,58 µg/mL ± 19,07                                  |
| Stem        | 168,46 µg/mL ± 5,83                                   |
| Root        | 293,81 µg/mL ± 12,40                                  |
| Doxorubicin | 208,82 nM ± 22,95                                     |


Description:

<sup>\*</sup>SD : standard deviation in treatment with 3x repetition**Table 4.** Correlation test result of orphenadrine and cytotoxic activity


|                     |                     | Orphenadrine        | T47D cell           |
|---------------------|---------------------|---------------------|---------------------|
| <b>Orphenadrine</b> | Pearson correlation | 1                   | -.859 <sup>**</sup> |
|                     | Sig. (2-tailed)     |                     | .003 <sup>*</sup>   |
| <b>T47D cell</b>    | Pearson correlation | -.859 <sup>**</sup> | 1                   |
|                     | Sig. (2-tailed)     | .003 <sup>*</sup>   |                     |
| <b>Vero cell</b>    | Pearson correlation | -.872 <sup>**</sup> |                     |
|                     | Sig. (2-tailed)     | .002 <sup>*</sup>   |                     |

Description:

<sup>\*</sup> : p < 0.05<sup>\*\*</sup>: Correlations negative**Figure 1.** Results of identification *C. cinerariifolium* with TLC Visualyzer. Silica gel GF254 as Stationary phase, n-hexane: ethyl acetate 4:1 as mobile phase. Root extract (ER); stems extract (ES); flower extract (EF); and leave extract (EL). (A) TLC plates with UV 366 light not derivated, and (B) with derivated.



**Figure 2.** The results of chromatogram *C. cinerariifolium* extract. A) Chromatogram of roots extract; B) Chromatogram of stems extract; C) Chromatogram of leaves extract; D) Chromatogram of flowers extract.



**Figure 3.** Spectra m/z and structure of *Orphenadrine*




Figure 4. Spectra m/z and structure of *D-(-)-Morphine*



Figure 5. Spectra m/z and structure of *N-[(5-Chloro-1,2,3-thiadiazol-4-yl)methyl]-1-(2-isopropyl-4-methyl-1,3-thiazol-5-yl)-N-methylethanamine*






Figure 6. Spectra m/z and structure of *Genistein*



**Figure 7.** The results of statistical analysis using Principal Component Analysis (PCA). A) Loading plot shows marker compound; B) Show plot closeness compound score on the part of *C. cinerariifolium*; C) Score plot shows compound compounds which have similarity and difference physical and chemical characteristic.



**Figure 8.** Viability of T47D cells due to the administration of the flowers, stem leaves and roots of extract *C. cinerariifolium* (A). Viability of T47D cells due to the administration of doxorubicin as a comparison.